Trial Profile
IMMULAB - A Phase II Trial of Immunotherapy With Pembrolizumab in Combination With Local Ablation for Patients With Early Stage Hepatocellular Carcinoma (HCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms IMMULAB
- 21 Jan 2023 Primary endpoint (Objective response rate (ORR) according to RECIST 1.1) has not been met, according to Results presented at the 2023 Gastrointestinal Cancers Symposium.
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 10 Nov 2022 Status changed from recruiting to active, no longer recruiting.